Management of muscle-invasive bladder cancer: an update

Ghoneim, Mohamed A.; Abol‐Enein, Hassan

doi:10.1038/ncpuro1202

Cited by 24 publications

(15 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only 20% of bladder cancer patients are diagnosed with MIBC, which causes most cancer-specific deaths. Although radical cystectomy is considered the gold standard for the treatment of patients with localized MIBC, about 50% of these patients develop metastases within 2 years after cystectomy and subsequently die of the disease [6]. …”

Section: Introductionmentioning

confidence: 99%

DecreasedDBC1Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer

et al. 2013

View full text Add to dashboard Cite

PurposeThe deleted in bladder cancer 1 (DBC1) gene is located within chromosome 9 (9q32-33), a chromosomal region that frequently shows loss of heterozygosity in bladder cancer (BC). It is suspected that it acts as a tumor suppressor gene, but its prognostic value remains unclear. The aim of the present study was to investigate the value of DBC1 as a prognostic marker in BC.Materials and MethodsThe expression of DBC1 was determined by real-time polymerase chain reaction analysis in 344 patients with BC (220 non-muscle-invasive BC [NMIBC] and 124 muscle-invasive BC [MIBC]) and in 34 patients with normal bladder mucosa. The results were compared with clinicopathologic parameters, and the prognostic value of DBC1 was evaluated by Kaplan-Meier analysis and a multivariate Cox regression model.ResultsDBC1 expression was significantly decreased in patients with MIBC compared with those diagnosed with NMIBC (p=0.010). Patients with aggressive tumor characteristics had lower DBC1 expression levels in NMIBC (each, p<0.05). By multivariate Cox regression analysis, low DBC1 expression was a predictor of progression to MIBC (hazard ratio, 7.104; p=0.013). Kaplan-Meier estimates revealed a significant difference in tumor recurrence, progression to MIBC, and cancer-specific survival depending on the level of DBC1 expression in NMIBC (log-rank test, each, p<0.05).ConclusionsThe expression of DBC1 was associated with tumor aggressiveness, progression to MIBC, and survival in NMIBC. Our results suggest that DBC1 expression can be a useful prognostic marker for patients with NMIBC.

show abstract

Section: Introductionmentioning

confidence: 99%

DecreasedDBC1Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Bladder cancer (BC) is the second‐leading common genitourinary malignancy, and about 30% of patients represent with or progress to disease invading bladder muscle [1]. Although radical cystectomy is performed in patients with invasive BC, half of the patients progress to an advanced stage with metastasis, and most of these die from this aggressive disease within 5 years [2]. Cisplatin‐based systemic chemotherapy with or without radical cystectomy has been empirically adapted with the aim of improving the prognosis of invasive or metastatic BC.…”

Section: Introductionmentioning

confidence: 99%

Twist1 and Y‐box‐binding protein‐1 promote malignant potential in bladder cancer cells

et al. 2010

View full text Add to dashboard Cite

What’s known on the subject? and What does the study add? So far, transcription factor Twist1 has been reported to regulate Y‐box binding protein‐1 (YB‐1) expression and play important roles in tumour growth, invasion and drug resistance. This study revealed that in bladder cancer cells, Twist1 regulated YB‐1 transcription and both Twist1 and YB‐1 promote malignant potentials including tumour growth, invasion and anticancer‐drug resistance. Although the relation between Twist1/YB‐1 signaling and cancer malignant potentials including tumour growth, invasion and anticancer‐drug resistance have been suggested, their roles in bladder cancer remain unknown. This study revealed their functional importance in bladder cancer, indicating that both Twist1 and YB‐1 are promising molecular targets in bladder cancer. OBJECTIVE • To investigate the roles of Twist1 and Y‐box binding protein‐1 (YB‐1) and their potential as therapeutic targets in bladder cancer (BC), as both have been suggested to play important roles in tumour growth, invasion and drug resistance. MATERIALS AND METHODS • Bladder cancer cell lines (TCCsup, UMUC3, T24 and KK47 cells) were used. • Twist1 and YB‐1 expression levels were assessed by luciferase reporter assay, quantitative real‐time polymerase chain reaction (PCR) and western blot analysis. • Tumour growth and cell cycle were analysed by cell proliferation assay and flow cytometry, respectively. • Invasive and motile abilities were investigated by scratch‐wound test and migration assay, respectively. Cytotoxicity assay was performed to determine drug sensitivity. RESULTS • The findings showed that Twist1 regulated YB‐1 expression in BC cells. • Both Twist1 and YB‐1 were involved in cell growth, invasion, motility and resistance to cisplatin and doxorubicin, but not to 5‐fluorouracil (5‐FU). CONCLUSION • The present study showed that Twist1 regulates YB‐1 expression and that both Twist1 and YB‐1 promote malignant potentials, including tumour growth, invasion and anti‐cancer‐drug resistance, indicating that both Twist1 and YB‐1 are novel molecular targets in BC.

show abstract

“…Bladder cancer (BC) is a public health problem throughout the world, and most of the cases are presented as urothelial cell carcinoma . Recently, radical cystectomy (RC) has been introduced as a standard treatment for BC invading muscle (muscle‐invasive BC [MIBC]) and some BCs not invading muscle (non‐muscle‐invasive BC [NMIBC]), such as multiple recurrent high‐grade tumours, high‐grade T1 tumours and high‐grade tumours with concurrent carcinoma in situ . The standard of RC is radical cystoprostatectomy for men and anterior exenteration (including bladder, urethra, uterus and ventral vaginal wall) for women .…”

Section: Introductionmentioning

confidence: 99%

Laparoscopic pelvic lymph node dissection system based on preoperative primary tumour stage (T stage) by computed tomography in urothelial bladder cancer: results of a single‐institution prospective study

Yuan

Miao

et al. 2013

BJU International

View full text Add to dashboard Cite

What's known on the subject? and What does the study add?• Bladder cancer (BC) is a public health problem throughout the world, and now radical cystectomy (RC) has been introduced as a standard treatment for BC invading muscle and some BCs not invading muscle. Pelvic lymph node dissection (PLND) is considered an integral part of RC for its prognostic and therapeutic significance, but the extent of the PLND has not been precisely defined.• Computed tomography is considered one of the most preferable methods to assess the BC stage preoperatively because of its high sensitivity and specificity. However, there are few articles referring to CT as an aid in deciding the extent of lymphadenectomy during RC.• In the present study, we prospectively studied the clinical value of preoperative CT staging of primary tumours in deciding the extent of PLND during laparoscopic RC in the management of BC. The preliminary findings suggested that all patients with higher preoperative CT stage should be given super-extended PLND during RC. For those with lower CT stage, careful and thorough clearance of all lymphatic and adipose tissues within the true pelvis could be more helpful than super-extended PLND.

show abstract

Management of muscle-invasive bladder cancer: an update

Cited by 24 publications

References 57 publications

DecreasedDBC1Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer

DecreasedDBC1Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer

Twist1 and Y‐box‐binding protein‐1 promote malignant potential in bladder cancer cells

Laparoscopic pelvic lymph node dissection system based on preoperative primary tumour stage (T stage) by computed tomography in urothelial bladder cancer: results of a single‐institution prospective study

Contact Info

Product

Resources

About